Peptide 51(ATWLPVPVVGYFMASA) selected by Larimer and Deutscher (Larimer and Deutscher, 2014) was used to target BT-474 human breast cancer and other HER2 positive cancers in order to reduce the non-target accumulation in other tissues (Figure 2). Here, ERBB2 is linked to breast cancer.